The correlation between incidence of metabolic syndrome and sociodemographic and clinical characteristics in schizophrenia patients

Amaç: Bu çalışmada, antipsikotik ilaçlarla tedavi altında olan şizofreni hastalarında metabolik sendrom (MetS) sıklığı ve metabolik sendromlu hastaların sosyodemografik ve klinik özelliklerinin saptanması amaçlanmıştır. Yöntem: DSM-IV tanı kriterlerine göre tanısı konan ve en az 3 aydır antipsikotik tedavi almakta olan 111 şizofreni hastası çalışmaya alındı. MetS tanısı Uluslararası Diyabet Fedarasyonu (IDF) tanı kriterlerine göre kondu. MetS tanısı konan ve konmayan hasta grupları arasında sosyodemografik ve klinik özellikler açısından karşılaştırma yapıldı. Bulgular: Hastaların %27’sinde MetS saptandı. En sık saptanan kriter, bel çevresi genişliğiydi (%65.8). Sıklığı en az olan kriter ise kan basıncı yüksekliğiydi (%10.8). Bel çevresi genişliği kriteri kadınlarda, kan basıncı yüksekliği kriteri ise erkeklerde daha sık karşılandı. MetS’i olan ve olmayan şizofreni hastaları arasında sosyodemografik özellikler, şizofreni tipi, semptomları ve diğer klinik özellikler açısından fark saptanmadı. Sonuç: Antipsikotik tedavi altında olan şizofreni hastalarında MetS önemli bir sorundur. Bel çevresi genişliği takipte önemli bir kriterdir. Literatürde MetS ile sosyodemografik ve klinik özelliklerin ilişkisine dair bulgular çelişkilidir. Bizim çalışmamızda ilişki saptanmamıştır. Bu konuyu aydınlatmak için daha fazla sayıda çalışmaya ihtiyaç vardır. MetS ile şizofreni alt tipleri ve şizofreni semptomları ilişkisiz gibi görünmektedir.

Şizofreni hastalarında metabolik sendrom sıklığının sosyodemografik ve klinik özelliklerle ilişkisi

Objective: The purpose of this study was to determine the frequency of metabolic syndrome (MetS) in schizophrenia patients who are receiving treatment with antipsychotic drugs and also the sociodemographic and clinical characteristics of schizophrenia patients with MetS. Methods: 111 schizophrenia patients diagnosed on the basis of DSM-IV diagnostic criteria and receiving antipsychotic therapy for at least 3 months were included in the study. MetS was diagnosed on the basis of International Diabetes Fedaration (IDF) diagnostic criteria. Schizophrenia patient groups with and without diagnosed MetS were compared in terms of sociodemographic and clinical characteristics. Results: MetS was determined in 27% of the patients. The most commonly determined parameter was elevated waist circumference (65.8%). The least common parameter was elevated blood pressure (10.8%). The waist circumference parameter in women and the blood pressure parameter in men were more frequently determined. No difference was determined between schizophrenia patients with or without MetS in terms of sociodemographic characteristics, schizophrenia subtypes and symptoms or other clinical characteristics. Conclusion: MetS is a significant problem in schizophrenia patients receiving antipsychotic therapy. Elevated waist circumference is an important parameter in monitoring. The findings in the literature regarding the relationship between MetS and sociodemographic and clinical characteristics are contradictory. No correlation was determined in our study. Further studies are now needed to shed light on this subject. There would seem to be no correlation between MetS and schizophrenia subtypes and symptoms.

___

  • 1. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr Bull 2013; 39:306-318.
  • 2. Riordan HJ, Antonini P, Murphy MF. Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications. American Health & Drug Benefits 2011; 4:292-302.
  • 3. Wagenknecht LE, Langefeld CD, Scherzinger AL, Norris JM, Haffner SM, Saad MF, Bergman RN. Insulin sensitivity, insulin secretion, and abdominal fat: the insulin resistance atherosclerosis study (IRAS) Family study. Diabetes 2003; 52:2490-2496.
  • 4. Holt RI, Peveler RC, Byrne CD. Schizophrenia, the metabolic syndrome and diabetes. Diabet Med 2004; 21:515-523.
  • 5. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montoni VM. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and metaanalysis of longitudinal studies. J Am Coll Cardiol 2007; 49:403-414.
  • 6. Kozumplik O, Uzun S, Jakovljević M. Metabolic syndrome in patients with psychotic disorders: diagnostic issues, comorbidity and side effects of antipsychotics. Psychiatr Danub 2010; 22:69- 74.
  • 7. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009; 119:4-14.
  • 8. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
  • 9. Meyer J, Koro CE, L’Italien GJ. The metabolic syndrome and schizophrenia: a review. Int Rev Psychiatry 2005; 17:173-180.
  • 10. Keltner NL. Biological perspectives. Metabolic syndrome: schizophrenia and atypical antipsychotics. Perspect Psychiatr Care 2006;42:204-207.
  • 11. Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, Lieberman JA; CAFE Investigators. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res 2009; 111:9-16.
  • 12. Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, De Hert M. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol 2011; 26:291-302.
  • 13. Subashini R, Deepa M, Padmavati R, Thara R, Mohan V. Prevalence of diabetes, obesity and metabolic syndrome in subjects with and without schizophrenia (CURES-104). J Postgrad Med 2011; 57:272-277.
  • 14. Sugawara N, Yasui-Furukori N, Sato Y, Umeda T, Kishida I, Yamashita H, Saito M, Furukori H, Nakagami T, Hatakeyama M, Nakaji S, Kaneko S. Prevalence of metabolic syndrome among patients with schizophrenia in Japan. Schizophr Res 2010; 123:244-250.
  • 15. Sugawara N, Yasui-Furukori N, Sato Y, Kishida I, Yamashita H, Saito M, Furukori H, Nakagami T, Hatakeyama M, Kaneko S. Comparison of prevalence of metabolic syndrome in hospital and community-based Japanese patients with schizophrenia. Ann Gen Psychiatry 2011;10:21.
  • 16. Kaponen HJ, Hakko HH, Saari KM, Lindeman SM, Karvonen KM, İsohanni MK, Lauren LH, Savolainen MJ, Järvelin MR. The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: a Northern Finland 1966 birth cohort. World J Biol Psychiatry 2010; 11:262-267.
  • 17. De Hert M, van Vinkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006; 83:87-93.
  • 18. Tirupati S, Chua LE. Body mass index as a screening test for metabolic syndrome in schizophrenia and schizoaffective disorders. Australas Psychiatry 2007; 15:470-473.
  • 19. Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusuraisin N. Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow up study. BMC 2007; 7:14.
  • 20. Kurt E, Altinbas K, Alatas G, Ozver I. Metabolic syndrome prevalence among schizophrenic patients treated in chronic inpatient clinics. Psychiatry in Türkiye 2007; 9:141-145 (in Turkish).
  • 21. Saddichha S, Ameen S, Akhtar S. Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six-week prospective study in Indian female patients. Schizophr Res 2007; 95:247.
  • 22. Saddichha S, Maniunatha N, Ameen S, Akhtar S. Metabolic syndrome in first episode schizophrenia: a randomized doubleblind controlled, short-term prospective study. Schizophr Res 2008; 101:266-272.
  • 23. Cerit C, Ozten E, Yildiz M. The prevalence of metabolic syndrome and related factors in patients with schizophrenia. Turk Psikiyatri Derg 2008; 19:124-132.
  • 24. Cerit C, Vural M, Bos Gelmez SU, Ozten E, Aker AT, Yildiz M. Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study. Psychopharmacol Bull 2010; 43:22-236.
  • 25. Boke O, Aker S, Sarisoy G, Saricicek EB, Sahin AR. Prevalence of metabolic syndrome among inpatients with schizophrenia. Int J Psychiatry Med 2008; 38:103-112.
  • 26. Kaya MC, Virit O, Altindag A, Selek S, Bulbul F, Bulut M, Savas HA. Prevalence of metabolic syndrome, characteristics of metabolic syndrome and relationship with the antipsychotics used in schizophrenia. Archives of Neuropsychiatry 2009; 46:13- 18 (in Turkish).
  • 27. Yazici MK, Anil Yagcioglu AE, Ertugrul A, Eni N, Karahan S, Karaagaoglu E, Tokgozoglu SL. The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey. Eur Arch Psychiatry Clin Neurosci 2011; 261:69-78.
  • 28. Grover S, Aggarwal M, Dutt A, Chakrabarti S, Avasthi A, Kulhara P, Somaiya M, Malhotra N, Chauhan N. Prevalence of metabolic syndrome in patients with schizophrenia in India. Psychiatry Res 2012; 200: 1035-1037.
  • 29. Guveli H, Ilnem MC, Yener F, Karamustafalioglu N, Ipekcioglu D, Abanoz Z. The frequency of metabolic syndrome in schizoprenia patients using antipsychotic medication and related factors. New Symposium 2011; 49:67-76 (in Turkish).
  • 30. Bou Khalil R. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-euro-american societies. Clin Neuropharmacol 2012; 35:141-147.
  • 31. Pallava A, Chadda RK, Sood M, Lakshmy R. Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/ naïve and antipsychotic-treated patients from India. Nord J Psychiatry 2012; 66:215-221.
  • 32. Oyeckin DG. The frequency of metabolic syndrome in patients with schizophrenia and schizoaffective disorder. Anatolian Journal of Psychiatry 2009; 10:26-33 (in Turkish).
  • 33. Hägg S, Lindblom Y, Mjörndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006; 21:93-98.
  • 34. Bai YM, Chen TT, Yang WS, Chi YC, Lin CC, Liou YJ, Wang YC, Su TP, Chou P, Chen JY. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. Schizophr Res 2009; 111:1-8.
  • 35. Huang MC, Lu ML, Tsai CJ, Chen PY, Chiu CC, Jian DL, Lin KM, Chen CH. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 2009; 120:274-280.
  • 36. Kato MM, Currier MB, Gomez CM, Hall L, Gonzalez-Blanco M. Prevalence of metabolic syndrome in hispanic and non-hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry 2004; 6:74-77.
  • 37. Straker D, Correll CU, Kramer-Ginsberg E, Abdulhamid N, Koshy F, Rubens E, Saint-Vil R, Kane JM, Manu P. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry 2005; 162:1217-1221.
  • 38. Kang SH, Kim KH, Kang GY, Lee KH, Kim KK, Soh M, Ahn KJ, Kim SH, Lee JI. Cross-sectional prevalence of metabolic syndrome in Korean patients with schizophrenia. Schizophr Res 2011; 128:179-181.
  • 39. Kagal UA, Torgal SS, Patil NM, Malleshappa A. Prevalence of the metabolic syndrome in schizophrenic patients receiving secondgeneration antipsychotic agents--a cross-sectional study. Pharm Pract 2012; 25:368-373.
  • 40. De Hert M, Schreurs V, Vancampfort D, VAN Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009; 8:15-22.
  • 41. Gautam S, Meena PS. Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (secondgeneration) antipsychotics. Indian J Psychiatry 2011; 53:128-133.
  • 42. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007; 89:91-100.
  • 43. Koroglu E. Psikiyatride Hastalıkların Tanımlanması Ve Sınıflandırılması Elkitabı, Gözden Geçirilmiş Dördüncü Baskı (DSM-IV-TR). Amerikan Psikiyatri Birliği, Washington DC, 2000’den çeviri, Hekimler Yayın Birliği. Ankara, 2001 (DSM-IVTR in Turkish).
  • 44. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-275.
  • 45. Kostakoglu AE, Batur S, Tiryaki A, Gogus A. Reliability and validity of the Turkish version of the Positive and Negative Syndrome Scale (PANSS). Turkish Journal of Psychology 1999; 14:23-32 (in Turkish).
  • 46. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366:1059-1062.
  • 47. Padmavati R, McCreadie RG, Tirupati S. Low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia. Schizophr Res 2010; 121:199-202.
  • 48. Sanisoglu SY, Oktenli C, Hasimi A, Yokusoglu M, Ugurlu M. Prevalence of metabolic syndrome-related disorders in a large adult population in Turkey. BMC Public Health 2006; 6:92.
  • 49. Kozan O, Oguz A, Abaci A, Erol C, Ongen Z, Temizhan A, Celik S. Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr 2007; 61:548-553.
  • 50. De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health 2006; 2:14.
Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi-Cover
  • ISSN: 1018-8681
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 1984
  • Yayıncı: Kare Yayıncılık
Sayıdaki Diğer Makaleler

The correlation between incidence of metabolic syndrome and sociodemographic and clinical characteristics in schizophrenia patients

GÖKHAN SARISOY, Ömer BÖKE, Arif ÖZTÜRK, Derya AKKAYA, Ozan PAZVANTOĞLU, AHMET RİFAT ŞAHİN

Personality changes in a patient with Wilson’s disease

Esra Sena GENÇ, Abdullah GENÇ, Neşe GÜVENEROĞLU ÜSTÜN

Mania/hypomania associated with withdrawal of antidepressants

Mehmet GÜDÜK, İlke Yeşer ERENSOY, Filiz ERSÜMER

Depression-anxiety levels and the quality of life among children and adolescents with coeliac disease

SANİYE TÜLİN FİDAN, Vildan ERTEKİN, Kezban KARABAG

Dikkat eksikliği hiperaktivite bozukluğu alt tiplerinin aile işlevleri üzerindeki etkisi

A. Şebnem SOYSAL, Ayşegül YILDIRIM, Aktan ACAR, BAŞAK KARATEKE, KIZBES MERAL KILIÇ

Personality dimensions and defense styles that are related with relapse during 12 month follow-up in male alcohol dependents

Cüneyt EVREN, Sera YİĞİTER, MÜGE BOZKURT, Dilara ÇAĞIL, SERAP ÖZÇETİNKAYA ERDOĞAN, FATMA YEŞİM CAN, ELİF MUTLU

Cerebral venous sinus thrombosis: gender differences in ten years experience

Tuba ÖZCAN AYDEMİR, Hasan MERAL, Serkan ÖZBEN, Raziye TİRAŞ, Hüsniye HAKYEMEZ, Oya ÖZTÜRK, Aytül MUTLU, Özlem ÇOKAR, Feriha ÖZER, Belgin BALCI PETEK

Bupropion ınduced ıncrease in sexual desire in a patient on fluoxetine treatment

Filiz İZCİ, Selma ZİNCİR BOZKURT, Güler ACAR, Umit SEMİZ BAŞAR

The relationship between dysfunctional attitudes, rumination response styles and depression

ÖMER ŞENORMANCI, Ramazan KONKAN, Oya GÜÇLÜ, Güliz ŞENORMANCI, Mehmet Zihni SUNGUR

Low frequency (1 Hz) rTMS application in the treatment of resistant auditory hallucinations: A case presentation

ATİLLA TEKİN, Bahadır BAKIM, Esra ÖZDİL, Mehmet Diyaddin GÜLEKEN